Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating
Credit Suisse Lowers Fulgent Genetics' Price Target to $45 From $50 After Mixed Q4 Results, Keeps Outperform Rating
在第四季度业绩喜忧参半之后,瑞士信贷将Fulgent Genetics的目标股价从50美元下调至45美元,维持跑赢大盘的评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册